ALETA-001: A phase 1 and 2 trial of ALETA-001 in patients with relapsed or refractory non-Hodgkin lymphoma

This trial is testing the novel chimeric antigen receptor (CAR) T-cell engager ALETA-001 in patients with non-Hodgkin lymphoma (NHL) which has returned after (relapsed) or not responded to (refractory) treatment.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT06045910

Trial aim and background  

The aim of this trial is to investigate the medication ALETA-001 which is a novel CAR-T cell engager. The first phase will aim to define a recommended dosing level and the second phase will look at the safety and efficacy, as well as how well tolerated it is.

Part of this trial is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter 

Patients over 16 with NHL which has not responded to, or relapsed within 9 months of receiving a CAR-T treatment may be eligible for this trial. 

Locations 

Recruitment is taking place in the following UK locations:

  • University Hospital Birmingham NHS Foundation Trust, Birmingham
  • Cambridge University Hospitals, Cambridge

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT06045910

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.